The few patients who had post-rituximab immunosuppression using obinutuzumab, belimumab, tocilizumab, Janus kinase inhibitors or TNF-α blockers were under occasional special circumstances, mostly due to an overlap syndrome (e.g. RA). The gene discussed is TNF; the disease is connective tissue disorder.